Scientific Reports (May 2024)

Cervical percutaneous interferential current stimulation improves citric acid cough tests in patients with Parkinson’s disease on medication

  • Masahiro Nakamori,
  • Megumi Toko,
  • Hidetada Yamada,
  • Yuki Hayashi,
  • Kai Ushio,
  • Kohei Yoshikawa,
  • Aya Hiraoka,
  • Mineka Yoshikawa,
  • Toshikazu Nagasaki,
  • Yoshitaka Shimizu,
  • Yukio Mikami,
  • Hirofumi Maruyama

DOI
https://doi.org/10.1038/s41598-024-62460-x
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Aspiration pneumonia is the leading cause of death in patients with Parkinson’s disease. The incidence of silent aspiration is high in such patients owing to decreased pharyngeal and laryngeal sensation; thus, interventions for this condition may help prevent pneumonia. In this single-arm, open-label study, we used a cervical percutaneous interferential current stimulation device to activate pharyngeal and laryngeal sensory nerves. We evaluated its effectiveness in patients with Hoehn–Yahr stages 2–4 Parkinson’s disease. The primary endpoint was the proportion of patients with a normal cough reflex after consuming 1% citric acid at the end of the intervention compared with baseline measurements. In total, 25 patients received neck percutaneous interferential current stimulation for 20 min twice weekly for 8 weeks. Afterward, the proportion of patients with a normal cough reflex after 1% citric acid consumption increased significantly (p = 0.001), whereas other indicators, such as tongue pressure, peak expiratory flow, and penetration or aspiration during videofluoroscopic examination, remained unchanged. A longer duration of illness, higher Unified Parkinson’s Disease Rating Scale total scores, and higher levodopa equivalent daily doses were significantly associated with improved cough test outcomes. Hence, cervical percutaneous interferential current stimulation significantly improved cough reflexes and may improve silent aspiration. Trial Registration: Japan Registry of Clinical Trials, jRCTs062220013, first registered 09/05/2022.